Provided by Tiger Fintech (Singapore) Pte. Ltd.

Trevi Therapeutics, Inc.

6.91
+0.60009.51%
Volume:1.58M
Turnover:10.59M
Market Cap:668.07M
PE:-14.71
High:7.02
Open:6.25
Low:6.14
Close:6.31
Loading ...

Trevi Therapeutics: Announce Positive Topline Results From Its Phase 2a River Trial of Haduvio for Treatment of Patients With Rcc (N=66)

THOMSON REUTERS
·
10 Mar

Trevi Therapeutics Inc: Haduvio Met Primary Endpoint

THOMSON REUTERS
·
10 Mar

Trevi Therapeutics Announces Positive Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough

PR Newswire
·
10 Mar

Trevi Therapeutics to Host Conference Call and Webcast on March 10th to Share Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough

PR Newswire
·
10 Mar

Trevi Therapeutics to Participate in Upcoming March Investor Conferences

PR Newswire
·
27 Feb

B.Riley Financial Sticks to Its Buy Rating for Trevi Therapeutics (TRVI)

TIPRANKS
·
26 Feb

BRIEF-Trevi Therapeutics Completes Enrollment For Phase 2B Coral Trial

Reuters
·
25 Feb

Trevi Therapeutics Completes Enrollment for Phase 2B Coral Trial of Haduvio in Idiopathic Pulmonary Fibrosis Patients With Chronic Cough

THOMSON REUTERS
·
25 Feb

Trevi Therapeutics Inc - Topline Results Expected in First Half of 2025

THOMSON REUTERS
·
25 Feb

Trevi Therapeutics Completes Enrollment for Phase 2b CORAL Trial of Haduvio in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough

PR Newswire
·
25 Feb

Analysts Offer Insights on Healthcare Companies: Trevi Therapeutics (TRVI), Astrana Health (ASTH) and Penumbra (PEN)

TIPRANKS
·
25 Feb

Stifel Nicolaus Keeps Their Buy Rating on Trevi Therapeutics (TRVI)

TIPRANKS
·
25 Feb

Trevi Therapeutics Is Maintained at Buy by D. Boral Capital

Dow Jones
·
24 Feb

Trevi Therapeutics, Inc. : Oppenheimer Raises Target Price to $12 From $9

THOMSON REUTERS
·
21 Feb

What Makes Trevi Therapeutics (TRVI) a New Buy Stock

Zacks
·
09 Jan

B. Riley Adjusts Trevi Therapeutics' Price Target to $11 From $6, Maintains Buy Rating

MT Newswires Live
·
08 Jan

Trevi Therapeutics Prices $50 Million Underwritten Offering

MT Newswires Live
·
16 Dec 2024

Trevi Therapeutics Announces Pricing of $50 Million Underwritten Offering

THOMSON REUTERS
·
16 Dec 2024

Trevi Therapeutics Announces Pricing of $50 Million Underwritten Offering

PR Newswire
·
16 Dec 2024

Analysts Offer Insights on Healthcare Companies: Affimed (AFMD), Editas Medicine (EDIT) and Trevi Therapeutics (TRVI)

TIPRANKS
·
16 Dec 2024